Biogen Inc
Company Profile
Business description
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Contact
225 Binney Street
CambridgeMA02142
USAT: +1 617 679-2000
E: IR@biogen.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
7,605
Biogen Inc News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
stocks
24 stocks for 2030
stocks
3 top picks in global healthcare
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,205.00 | 1.70 | -0.02% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 26,050.08 | 232.61 | -0.89% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 52,211.69 | 886.08 | 1.73% |
| NZX 50 Index | 13,544.51 | 85.22 | 0.63% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,909.10 | 4.10 | -0.05% |
| SSE Composite Index | 3,961.62 | 25.28 | -0.63% |